Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Novocure, Pfizer Inc, and Takeda Oncology.

Community Practice Connections™: 20th Annual International Lung Cancer Congress®

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 20th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Benefits of Participating

  • Assess emerging paradigms in immunotherapy in lung cancer
  • Evaluate management approaches for patients with oncogene-driven non–small cell lung cancer
  • Discuss new approaches for biopsy and testing to personalize therapy in lung cancer
  • Incorporate personalized treatment strategies in the management of patients with lung cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Novocure, Pfizer Inc, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate biomarkers and testing strategies to optimize selection of therapy in patients with lung cancer.
  • Discuss emerging evidence concerning the management of patients with nonmetastatic lung cancer.
  • Incorporate recent data sets on single-agent and combination immunotherapeutic approaches to care for patients with advanced thoracic malignancies.
  • Apply recent clinical data on targeted and cytotoxic strategies for the management of patients with thoracic malignancies.
  • Describe optimized and personalized sequencing strategies utilizing clinical trial evidence, performance status, and tumor characteristics.
  • Summarize the status of current clinical trials or approaches to address variances in care for patients with thoracic malignancies.

Faculty, Staff, and Planners’ Disclosures


David R. Gandara
David R. Gandara, MD
Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant Research Support: Bristol-Myers Squibb, Roche/Genentech, Novartis, Merck; Consultant: AstraZeneca, Celgene, CellMax, FujiFilm, Roche-Genentech, Guardant Health, Inivata, IO Biotech, Lilly Oncology, Liquid Genomics, Merck, Samsung Bioepis, Pfizer.

Roy S. Herbst
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosures: Grant Research Support: AstraZeneca, Eli Lilly and Company, Merck and Company; Consultant: AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Tesaro, Tocagen; Other: Junshi Pharmaceuticals, Board of Directors (nonexecutive/independent)

Corey J. Langer
Corey J. Langer, MD, FACP
Professor of Medicine
Hematology/Oncology Division
University of Pennsylvania
Director, Thoracic Oncology
Abramson Comprehensive Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Pfizer Inc, Eli Lilly and Company, Genentech/Roche Inc, OSI Pharmaceuticals Inc, GlaxoSmithKline, Merck, Nektar, Advantagene, Inovio, Ariad (Takeda), Stemcentrx (AbbVie), Celgene, Incyte, MacroGenics; Consultant: Bristol-Myers Squibb, ImClone Systems Inc, Eli Lilly and Company; AstraZeneca Pharmaceuticals LP, Merck, Novartis Pharmaceuticals Corporation, Genentech Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Celgene Oncology, Abbott Laboratories, Biodesix, Clariant, CarisDx, ARIAD Pharmaceuticals Inc, Boehringer Ingelheim, Synta Pharmaceuticals Corporation, Clovis; Other: DSMC: Lilly Oncology, Amgen, Peregrine, Synta, SWOG, Incyte, VA CME: PIK, NOCR, CCO, RTP

Solange Peters
Solange Peters, MD-PhD
Full Professor
Chair, Thoracic Malignancies
Head, Medical Oncology
Department of Oncology
Lausanne University Hospital
Lausanne, Switzerland

Disclosures: Grant/Research Support: Subinvestigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, Pfizer; Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda; Speakers Bureau: Gave talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly Oncology, F. Hoffman-La Roche, Illumina, Merck Sharp and Dohme, Novartis, Pfizer, Sanofi, Takeda.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By